Covance 2Q09
2Q Revenues: $466 million (+7%)
2Q Earnings: $43 million (-16%)
YTD Revenues: $907 million (+7%)
YTD Earnings: $83 million (-17%)
Comments: Early Development revenues dropped 6% in the quarter to $200 million, reflecting lower demand in toxicology services. Demand grew for clinical pharmacology, analytical chemistry and research services. Late-Stage Development revenues grew 19% to $266 million, driven by increases in demand for central lab services, as well as clinical development and commercialization services.
Sign up today for Contracting & Outsourcing 2009!
Magazine
